RxDoctor Payments Data

Jonathan Bryan, DO

Internal Medicine · Norman, OKNPI 1437363702

Payments from drug & device makers

$260in general payments, 2019–2025

Across 13 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$136
  • GSK$37
  • AbbVie$30
  • Boehringer Ingelheim$26
  • GE HealthCare$17
  • Novo Nordisk$15

What the payments were for

  • Food & beverage$260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer7$136
GSK2$37
AbbVie1$30
Boehringer Ingelheim1$26
GE HealthCare1$17
Novo Nordisk1$15

How this compares

$260 in reported general payments places this provider in the 50th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$190,505
Medicare patients
494
Services billed
2,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$158,031
JardianceEmpagliflozin76$114,971
TrulicityDulaglutide77$114,391
EliquisApixaban93$84,268
XareltoRivaroxaban43$46,282
MounjaroTirzepatide36$41,404
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$29,202
FarxigaDapagliflozin Propanediol25$23,388
VraylarCariprazine Hcl12$16,475
Spiriva HandihalerTiotropium Bromide17$13,724
Novolog FlexpenInsulin Aspart18$9,274
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$9,018
MyrbetriqMirabegron11$8,752
Atorvastatin Calcium417$5,401
Fluticasone Propionate225$4,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$158,03180 claims
Boehringer IngelheimJardiance$26$114,97176 claims
PfizerEliquis$136$84,26893 claims
GSKTrelegy Ellipta, Incruse Ellipta$37$33,25138 claims
AbbVieVraylar$30$16,47512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →